Patients with previously untreated advanced squamous non-small-cell lung cancer lived significantly longer without their disease worsening when treated with ivonescimab, a bispecific antibody targeting both PD-1 and VEGF, compared with a standard PD-1 inhibitor. The randomized, double-blind phase 3 trial called HARMONi-6 reported median progression-free survival of 11.1 months for ivonescimab plus chemotherapy versus 6.9 months for tislelizumab plus chemotherapy, a 40 percent reduction in the risk of disease progression or death. The results, published in The Lancet, represent the first head-to-head victory of a bispecific antibody over an established immunotherapy-chemotherapy combination in this cancer type.
Why dual PD-1 and VEGF blockade changes the treatment calculus
Squamous lung cancer has been one of the harder subtypes to treat with anti-angiogenic drugs. Bevacizumab, the most widely used VEGF-targeting agent, was historically excluded from squamous NSCLC regimens because of bleeding risks. That left PD-1 inhibitors combined with platinum-based chemotherapy as the default first-line approach. The FDA approved pembrolizumab plus chemotherapy for metastatic squamous NSCLC based on the KEYNOTE-407 trial, and that regimen has anchored standard care in the United States for years.
Ivonescimab sidesteps the old limitation by packaging PD-1 inhibition and VEGF blockade into a single engineered molecule rather than combining two separate drugs. The theory is straightforward: VEGF promotes the formation of blood vessels that feed tumors, and it also suppresses immune activity in the tumor environment. Blocking VEGF alongside PD-1 could restore immune surveillance while starving the tumor of its blood supply. The question was whether that dual mechanism would produce a measurable clinical advantage over PD-1 inhibition alone when both arms also received chemotherapy.
HARMONi-6 answered that question with a hazard ratio of 0.60 (95% CI 0.46 to 0.78; one-sided p less than 0.0001), according to the HARMONi-6 report. The 4.2-month difference in median progression-free survival is clinically meaningful in a disease where prior improvements over chemotherapy alone were measured in smaller increments. The control arm performed as expected: tislelizumab plus chemotherapy had already demonstrated clear superiority over chemotherapy alone in the RATIONALE-307 trial, a phase 3 study conducted in China. That track record makes the HARMONi-6 result harder to dismiss as a weak-comparator artifact.
What HARMONi-6 measured and where the data stands
HARMONi-6 enrolled patients with advanced squamous NSCLC who had not received prior systemic therapy. The trial was randomized and double-blind, meaning neither patients nor investigators knew which treatment a given participant received. Both arms combined their respective antibody with standard platinum-doublet chemotherapy. The primary endpoint was progression-free survival assessed by an independent review committee, with overall survival and objective response as key secondary endpoints.
The median 11.1 months of progression-free survival in the ivonescimab arm compares favorably not only with the 6.9 months in the tislelizumab arm but also with historical benchmarks. In KEYNOTE-407, which tested pembrolizumab with carboplatin and a taxane in metastatic squamous NSCLC, the immunotherapy combination showed clear progression-free and overall survival benefits over chemotherapy alone. However, no head-to-head comparison between pembrolizumab and ivonescimab has been conducted, so cross-trial comparisons must be interpreted cautiously.
Early overall survival data from HARMONi-6 are still maturing. The trial was powered primarily for progression-free survival, and longer follow-up will be needed to determine whether the PFS advantage translates into a statistically significant and clinically meaningful survival gain. Nonetheless, the magnitude of the PFS benefit, coupled with a higher depth and durability of response reported in the ivonescimab arm, suggests that the dual-targeting strategy is doing more than simply delaying radiographic progression by a few weeks.
Safety is a crucial consideration when combining anti-angiogenic and immunotherapy effects in a single molecule. The HARMONi-6 investigators reported a safety profile broadly consistent with the known toxicities of PD-1 inhibitors and VEGF blockade, including hypertension, proteinuria, and immune-related adverse events. Most events were manageable with standard dose modifications and supportive care, and treatment discontinuations due to adverse events were comparable between the two arms. Importantly, the bleeding complications that limited bevacizumab use in squamous NSCLC did not emerge as a prohibitive signal with ivonescimab in this setting.
Biomarkers and the role of PD-L1 expression
A key hypothesis emerging from the data is whether the added VEGF blockade provides its greatest edge in patients whose tumors express low levels of PD-L1, the protein that PD-1 inhibitors rely on to activate immune responses. In tumors with high PD-L1 expression, PD-1 blockade alone already generates strong responses. In low-PD-L1 tumors, where checkpoint inhibitors have historically underperformed, the anti-angiogenic component of ivonescimab could supply an independent mechanism of tumor control. If subgroup analyses confirm a disproportionate benefit in low-PD-L1 patients, that would reshape how oncologists select treatment for squamous lung cancer based on biomarker testing.
Exploratory analyses from HARMONi-6, as summarized in the ivonescimab trial record, suggest that the progression-free survival advantage is maintained across PD-L1 expression strata, with a numerically larger effect in tumors expressing PD-L1 on less than 1 percent of cells. These findings are not yet definitive, but they reinforce the biological rationale that VEGF-driven immunosuppression can be countered even when PD-L1 is scarce. Future correlative studies examining immune cell infiltration, angiogenic gene signatures, and circulating biomarkers may help clarify which patients derive the most benefit.
PD-L1 will not be the only biomarker of interest. Tumor mutational burden, co-occurring genomic alterations, and features of the tumor microenvironment may also influence response to dual PD-1 and VEGF blockade. As bispecific antibodies move into broader clinical testing, integrating these biomarkers into trial design will be essential to avoid a one-size-fits-all approach and to maximize the therapeutic window.
Positioning ivonescimab in a crowded first-line landscape
The practical challenge for clinicians is how to position ivonescimab relative to entrenched standards such as pembrolizumab plus chemotherapy. In many health systems, pembrolizumab-based regimens are deeply embedded in guidelines and reimbursement frameworks. Introducing a new bispecific will require not only regulatory approval but also convincing evidence of added value, whether in the form of superior survival, improved quality of life, or cost-effectiveness.
HARMONi-6 provides a strong proof-of-concept that dual PD-1 and VEGF targeting can outperform a modern PD-1–chemotherapy regimen in squamous NSCLC. Yet questions remain about generalizability beyond the trial population, which was predominantly treated in Asia, and about how ivonescimab compares with other PD-1 or PD-L1 inhibitors used globally. Real-world evidence and additional comparative studies will be needed to determine whether the benefits seen against tislelizumab extend to other checkpoint backbones.
There are also strategic considerations around sequencing. If ivonescimab moves into the first-line setting, it may limit the utility of subsequent VEGF inhibitors or alternative immunotherapy combinations, as tumors could evolve resistance mechanisms to both pathways simultaneously. On the other hand, using the most potent regimen upfront may offer the best chance for durable disease control in a cancer that often progresses rapidly.
What comes next for bispecific antibodies in lung cancer
Ivonescimab’s success in HARMONi-6 is likely to accelerate interest in bispecific antibodies that co-target immune checkpoints and angiogenic pathways. Other constructs are already in earlier phases of development, exploring different target pairs and dosing strategies. The broader question is whether bispecifics can consistently outperform combinations of separate monoclonal antibodies, not only in efficacy but also in safety, convenience, and cost.
For now, HARMONi-6 marks an important milestone: it shows that rationally designed bispecifics can deliver a clear clinical advantage over a contemporary standard in a difficult-to-treat lung cancer subtype. As regulators and guideline panels review the data, oncologists will be watching closely to see whether dual PD-1 and VEGF blockade becomes the new benchmark for first-line treatment of advanced squamous NSCLC, particularly for patients whose tumors have limited PD-L1 expression and few other effective options.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
